Valeant Pharmaceuticals International Inc. agreed to pay $8.7 billion in cash for Bausch & Lomb Holdings Incorporated in a deal announced May 27. The deal capped a successful investment in the contact lens manufacturer for private equity firm Warburg Pincus LLP, which paid $3.7 billion for Bausch & Lomb in 2007. It also served as a consolation prize for Valeant, which earlier this year explored an acquisition of rival generic drug manufacturer Actavis Inc., a deal that might have been worth in excess of $15 billion.
Those talks fell through in late April, and on May 20 Actavis agreed to buy specialty pharmaceuticals company Warner Chilcott plc for $5 billion in stock and $3.5 billion in assumed debt. Valeant moved on quickly as well and would significantly expand its eye care business with the acquisition of Bausch & Lomb. The company's investors led by Warburg Pincus will receive $4.5 billion, and Valeant will also pay down $4.2 billion in Bausch & Lomb debt. New York buyout shop Welsh, Carson, Anderson & Stowe also owns a stake in Bausch & Lomb.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
